IONS · Categories · Upgrades
IONS - Analyst upgrades
Ionis Pharmaceuticals Inc. (IONS) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for IONS
- Ionis Pharma upgraded by Analyst with a new price targetAnalyst upgraded Ionis Pharma from Neutral to Overweight and set a new price target of $80.00
- Ionis Pharma upgraded by Goldman with a new price targetGoldman upgraded Ionis Pharma from Sell to Neutral and set a new price target of $65.00
- Ionis Pharma upgraded by BMO Capital Markets with a new price targetBMO Capital Markets upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $70.00
- Ionis Pharma upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Ionis Pharma from Equal-Weight to Overweight and set a new price target of $62.00
- Ionis Pharma upgraded by Barclays with a new price targetBarclays upgraded Ionis Pharma from Equal Weight to Overweight and set a new price target of $57.00
- Ionis Pharma upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Ionis Pharma from Market Perform to Outperform and set a new price target of $62.00 from $53.00 previously
- Ionis Pharma upgraded by Bernstein with a new price targetBernstein upgraded Ionis Pharma from Underperform to Mkt Perform and set a new price target of $44.00
- Ionis Pharma upgraded by Wolfe Research with a new price targetWolfe Research upgraded Ionis Pharma from Peer Perform to Outperform and set a new price target of $58.00
- Ionis Pharma upgraded by BofA Securities with a new price targetBofA Securities upgraded Ionis Pharma from Neutral to Buy and set a new price target of $62.00 from $52.00 previously
- Ionis Pharma upgraded by BofA Securities with a new price targetBofA Securities upgraded Ionis Pharma from Underperform to Neutral and set a new price target of $52.00 from $33.00 previously
- Ionis Pharma upgraded by Citigroup with a new price targetCitigroup upgraded Ionis Pharma from Neutral to Buy and set a new price target of $60.00 from $36.00 previously
- Ionis Pharma upgraded by Citigroup with a new price targetCitigroup upgraded Ionis Pharma from Sell to Neutral and set a new price target of $36.00 from $30.00 previously
- Ionis Pharmaceuticals upgraded by William BlairWilliam Blair upgraded Ionis Pharmaceuticals from Market Perform to Outperform
- Ionis Pharma upgraded by UBS with a new price targetUBS upgraded Ionis Pharma from Sell to Neutral and set a new price target of $37.50 from $33.00 previously
- Ionis Pharma upgraded by Barclays with a new price targetBarclays upgraded Ionis Pharma from Underweight to Equal Weight and set a new price target of $52.00 from $50.00 previously